Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Third time lucky for Ipsen

Posted 17 June 2021 PM

Ipsen's Cabometyx will be expanded on the PBS as a first line treatment for stage IV advanced or metastatic clear cell variant renal cell carcinoma (RCC) as of July, saving patients around $120,000 a year, Health Minister Greg Hunt announced today (Thursday). 

Cabometyx has been available as a second line treatment for patients with advanced RCC since 2018. It took Ipsen three attempts to secure the new listing for treatment-naive patients.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs